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Abstract
BACKGROUND
Statins have an important and well-established role in the prevention of
atherosclerotic cardiovascular disease (ASCVD). However, several studies have
reported widespread underuse of statins in various practice settings and
populations. Review of relevant literature reveals opportunities for improvement
in the implementation of guideline-directed statin therapy (GDST).
AIM
To examine the impact of cardiologist intervention on the use of GDST in the
ambulatory setting.
METHODS
Patients with at least one encounter at the adult Internal Medicine Clinic (IMC)
and/or Cardiology Clinic (CC), who had an available serum cholesterol test
performed, were evaluated. The 2 comparison groups were defined as: (1)
Patients only seen by IMC; and (2) Patients seen by both IMC and CC. Patients
were excluded if variables needed for calculation of ASCVD risk scores were
lacking, and if demographic information lacked guideline-directed treatment
recommendations. Data were analyzed using student t-tests or χ2, as appropriate.
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additional data.

Analysis of Variance was used to compare rates of adherence to GDST.

STROBE statement: The authors

RESULTS
A total of 268 patients met the inclusion criteria for this study; 211 in the IMC
group and 57 in the IMC-CC group. Overall, 56% of patients were female, mean
age 56 years (± 10.65, SD), 22% Black or African American, 56% Hispanic/Latino,
14% had clinical ASCVD, 13% current smokers, 66% diabetic and 63%
hypertensive. Statin use was observed in 55% (n = 147/268) of the entire patient
cohort. In the IMC-CC group, 73.6% (n = 42/57) of patients were prescribed statin
therapy compared to 50.7% (n = 107/211) of patients in the IMC group (P = 0.002).
In terms of appropriate statin use based on guidelines, there was no statistical
difference between groups [IMC-CC group 61.4% (n = 35/57) vs IMC group,
55.5% (n = 117/211), P = 0.421]. Patients in the IMC-CC group were older, had
more cardiac risk factors and had higher proportions of non-white patients
compared to the IMC group (P < 0.02, all).
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CONCLUSION
Although overall use of GDST was suboptimal, there was no statistical difference
in appropriate statin use based on guidelines between groups managed by
general internists alone or co-managed with a cardiologist. These findings
highlight the need to design and implement strategies to improve adherence rates
to GDST across all specialties.
Key words: Statin use; Guideline directed statin therapy; Cardiologist; Ambulatory care;
Adherence
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Statins have an important and well-established role in the prevention of
atherosclerotic cardiovascular disease. However, several studies have reported widespread
underuse of statins in various practice settings and populations. Review of relevant
literature reveals opportunities for improvement in the implementation of guidelinedirected statin therapy (GDST). We aimed to examine the impact of cardiologist
intervention on adherence to GDST in the ambulatory setting. Our evaluation shows that
although overall adherence to GDST was suboptimal, there was no statistical difference in
appropriate statin use based on guidelines between groups managed by general internists
alone or co-managed with a cardiologist. These findings highlight the need to design and
implement strategies to improve adherence rates to GDST across all specialties.
Citation: Cassagnol M, Hai O, Sherali SA, D’Angelo K, Bass D, Zeltser R, Makaryus AN.
Impact of cardiologist intervention on guideline-directed use of statin therapy. World J Cardiol
2020; 12(8): 419-426
URL: https://www.wjgnet.com/1949-8462/full/v12/i8/419.htm
DOI: https://dx.doi.org/10.4330/wjc.v12.i8.419

INTRODUCTION
Statins have an important and well-established role in the prevention of atherosclerotic
cardiovascular disease (ASCVD). Large-scale clinical trials have shown that statins
substantially reduce cardiovascular morbidity and mortality in both primary and
secondary prevention. The American College of Cardiology/American Heart
Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce
ASCVD Risk in Adults emphasizes identifying and treating individuals at the highest
risk for developing ASCVD with statins[1,2]. However, despite mounting evidence
supporting its use, several studies have reported widespread underuse of statins in the
ambulatory setting[3], in secondary prevention[4], and more frequently among
women[5], older adults, Blacks, Hispanics/Latinos, and those who are under/uninsured[6]. Early skepticism of the feasibility of implementing the ACC/AHA
guidelines in a patient population has been documented. One report found 56%
predicted prescriber adherence to those guidelines in a retrospective simulated
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analysis of a large academic medical practice[6]. In a more recent study, one-third of
patients with ASCVD and almost one-half of patients without ASCVD were not
receiving guideline recommended moderate- to high-intensity statin therapy in
cardiology practices after the publication of the 2013 ACC/AHA guideline[1]. The most
recent cholesterol 2018 guidelines from ACC/AHA continue to emphasize the use of
statins as a primary treatment modality for eligible patients to achieve appropriate
low-density lipoprotein cholesterol (LDL-C) reduction[2].
Limited information is available regarding the appropriate implementation of the
cholesterol guidelines as they pertain to evidence-based statin use. The objective of our
study was to examine physician adherence to GDST in the ambulatory setting across
multiple subgroups of patients and determine the impact of cardiologist intervention
on GDST.

MATERIALS AND METHODS
Design and sample
A retrospective chart review was conducted of patients who had at least one encounter
at the adult Internal Medicine Clinic (IMC) and/or Cardiology Clinic (CC) at our
community tertiary care teaching hospital from May 2016 to April 2017 and who had
an available serum cholesterol test performed. Patients were excluded if the following
biometric variables needed for calculation of ASCVD risk score were unavailable: age,
sex, race, systolic blood pressure (SBP), total cholesterol (TC), LDL-C, high density
lipoprotein cholesterol (HDL-C), history of diabetes mellitus (DM), smoking status,
and hypertension treatment status. In addition, patients whose demographics lacked
guideline directed treatment recommendations were excluded (e.g., age < 40 or > 79
years). The 2 comparison groups were defined as: (1) Patients only seen by IMC; and
(2) Patients seen by both IMC and CC.

Definitions
The presence of clinical ASCVD included history of acute coronary syndrome, history
of myocardial infarction, stable or unstable angina, coronary or other arterial
revascularization, stroke, transient ischemic attack, or peripheral artery disease.
Moderate- and high-intensity statin was defined by statin dose that would lower LDLC on average by 30%-49% and ≥ 50% with daily dosing, respectively. Statin therapy
utilized was categorized as appropriate or not appropriate GDST. As such, the
presence of clinical ASCVD or LDL-C greater than 190 mg/dL, would indicate use of
high-intensity satin (atorvastatin 40–80 mg or equivalent)[1]. For primary prevention,
the presence of a diagnosis of DM and/or ASCVD risk score > 7.5% would indicate the
use of at least a moderate-intensity statin (atorvastatin 10-20 mg or equivalent)
depending on patient tolerance[1].

Data collection and assessment
Data collected included date of visit, date of lipid panel referenced, gender, age, body
mass index, race/ethnicity, TC, HDL-C, SBP, hypertension and its treatment status,
presence of clinically diagnosed DM, smoking status, history of ASCVD, clinically
diagnosed hyperlipidemia and current statin use including type and dose/intensity.
Data were entered into the ASCVD risk calculator, with 10-Year and lifetime ASCVD
risk recorded. Treatment assigned by the physician at the last clinic visit was then
compared to guideline recommended treatment, and labeled as appropriate or
inappropriate. If a patient’s LDL-C was greater than 190 mg/dL or if they had clinical
ASCVD, then they would be eligible for high-intensity statin and use of the ASCVD
risk calculator was not indicated and therefore not calculated, as per guideline
recommendations.

Statistical analysis
Descriptive statistics are presented as mean ± SD or number and percent. Baseline
characteristics of subgroups were compared using student t-tests or χ 2 tests, as
appropriate. χ2 test analysis was used to analyze statistical significance between
groups. Analysis of variance was used to test the statistical difference between means
of continuous variables. Statistical significance was defined as P < 0.05. All statistical
analyses were performed using SPSS version 26.0 (SPSSTM Inc., Chicago, IL, United
States).
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RESULTS
A total of 268 patients met the inclusion criteria for this study. Table 1 describes the
demographic characteristics of the study population, 56% were female, mean age was
56 years (± 10.65, SD), 22% identified as Black or African American and 56% identified
as Hispanic/Latino. Approximately 14% of the cohort had clinical ASCVD as
previously defined, 13% were current smokers, 66% were diabetic, and 63% were
hypertensive. Statin use was observed in 55% of the entire cohort, with moderateintensity statins being the most commonly prescribed.
Of the total 268 patients, 211 and 57 patients were in the IMC only and IMC-CC
group, respectively (Table 2). Overall, in the IMC-CC group, 73.6% (n = 42/57) of
patients were prescribed statin therapy compared to 50.7% (n = 107/211) of patients in
the IMC group (P = 0.002). In terms of appropriate statin use based on guidelines,
there was no statistical difference between groups [IMC-CC group 61.4% (n = 35/57)
vs IMC group, 55.5% (n = 117/211), P = 0.421]. Patients in the IMC-CC group had
significantly higher cardiac risk as compared to the IMC group: Clinical ASCVD
history (35.1% vs 18%, P < 0.001), diabetes (47.3% vs 30.3%, P = 0.016), hypertension
(80.7% vs 59.2%, P = 0.003) and smoking history (47.4% vs 26.1%, P = 0.002). Patients in
the IMC-CC group were significantly older (mean age 62.1 years vs 55.5 years, P <
0.001) and had a higher proportion of non-white patients (49.6% vs 29.4%, P = 0.021)
compared to the IMC group. Mean LDL-C and TC levels were lower in the IMC-CC
group vs the IMC group (mean LDL-C, 110.36 mg/dL vs 123.98 mg/dL, P = 0.013) and
(TC, 187.67 mg/dL vs 204.13, P = 0.018).

DISCUSSION
In our evaluation of real-world cholesterol management, we found that adherence to
GDST by physicians occurred in about half the patients eligible for statin therapy. The
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce ASCVD
Risk in Adults (which were the latest available guidelines during our study period)
recommends statins as first-line lipid lowering therapy for both primary and
secondary prevention[7]. Furthermore, data from the National Health and Nutrition
Examination Surveys estimated an increase in statin-eligible patients by 2.4 million, 2.2
million, and 8.2 million in patients with ASCVD, diabetes, and in primary prevention,
respectively[8]. Given recent shifts in the cholesterol treatment paradigm from the older
ATP III guidelines[9], Schoen et al[6] predicted 56% adherence with the 2013 blood
cholesterol guidelines in a retrospective analysis. In another study, Pokharel et al[7]
evaluated trends in the use of statin therapy and non-statin therapy in cardiology
practices, before and after the publication of the 2013 ACC/AHA guidelines. They
found modest, yet significant increases in the use of moderate- to high-intensity statins
in ASCVD patients and no change in the other statin benefit groups and nearly half of
statin eligible patients did not receive a statin[7]. By comparison, our real-world study
demonstrated similar trends in that nearly half of statin eligible patients did not
receive a statin. Furthermore, adherence to GDST by general internists tended to be
lower (55.5%) when compared to patients who were also being managed by a
cardiologist (61.4%), although this difference was not statistically significant. Hence,
being evaluated by a cardiology specialist did not appear to have any additional
impact on the use of GDST at our institution.
The literature also notes that different factors and patient characteristics affect
implementation and use of GDST. Schoen et al[10] found that women and patients with
diabetes were less likely to be treated optimally; and this in turn, could impact
cardiovascular outcomes. In our study, there was a higher proportion of patients with
clinical ASCVD and diabetes that were seen by the cardiologist. These patients also
had lipid profiles that necessitated therapy. This may suggest that at our institution,
higher risk patients needing further LDL-C reduction are appropriately being
managed by cardiology specialists who are trained to address these complex
situations. Furthermore, patients who were managed by the cardiologist achieved
significantly lower LDL-C levels, which may translate to greater reduction in future
coronary heart disease events[11]. Further long-term studies of these patients may shed
light on such outcomes.
Several other studies have reported similar trends in 2013 ACC/AHA guideline
implementation, however, very little is known about the barriers to adherence. Clough
et al[12] found that although community-based physicians often accurately estimated
risk, beliefs and approach to statin discussion varied and these variables had minimal
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Table 1 Patient Clinic demographics, n = 268, n (%)
Patient characteristics

Data

Age (yr), mean

56 (± 10.65, SD)

Sex
Male

118 (44)

Female

150 (56)

Race
White

180 (67.2)

Black

60 (22.2)

Other

28 (10.4)

Ethnicity
Hispanic/Latin-o,-a

151 (56.3)

Smoker
Never

184 (68.7)

Former

48 (17.9)

Current

34 (12.7)

Unknown

2 (0.7)

ASCVD

38 (14.2)

mean ASCVD score

12.1%

Diabetes

177 (66)

Hypertension

171 (63.8)

Statin prescribed

149 (55)

Low

11 (4.1)

Moderate

82 (30.6)

High

56 (20.9)

Clinical laboratory profile
TC (mg/dL), mean

200.63 (46.7, SD)

LDL-C (mg/dL), mean

121.08 (36.9, SD)

HDL-C (mg/dL), mean

51.17 (15.2, SD)

SBP (mmHg), mean

132 (19.2, SD)

TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol; SBP: Systolic blood pressure.

impact on low rates of statin prescribing. An inter-professional approach using the
patient-centered medical home model made no difference in guideline implementation
within a primary care practice[12]. It has been well established that it may take up to 17
years for evidence to be fully implemented into practice, which may explain the low
statin use in the overall study cohort[13]. More studies will need to be conducted to fully
understand these barriers. However, a recent study has shown that since the
publication of the 2013 ACC/AHA guidelines (and subsequent 2018 guidelines),
cholesterol levels and statin use have improved in the US[14]. Future studies should be
conducted to evaluate the long-term impact of the latest cholesterol guidelines on
adherence to GDST[15].
Our study has several limitations including the short period of analysis, its
retrospective design, and small sample size. As noted, studies have demonstrated that
it may take up to 17 years for evidence to be fully implemented into practice[13], and
therefore the period of analysis for our study [which occurred within 3 years (2016 to
2017) following guideline publication], may simply reflect the lag time between
guideline publication and implementation. Furthermore, our study relied on the
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Table 2 Adherence to guideline-directed statin therapy and patient characteristics by group, n (%)
All patients (n = 268)

IMC only (n = 211)

IMC/CC (n = 57)

P value

Statin prescribed

107 (50.7)

42 (73)

0.002

Appropriate intensity statin prescribed

117 (55.5)

35 (61.4)

0.421

Age(years), mean

55.47 (± 10.11, SD)

62.14 (± 11.08, SD)

< 0.001

ASCVD

18(8.5)

20 (35.1)

< 0.001

DM

64 (30.3)

27 (47.3)

0.016

Hypertension

125(59.2)

46 (80.70)

0.003

Smoking history (current and former)

55 (26.1)

27 (47.4)

0.002

Non-white

62 (29.4)

26 (45.6)

0.021

Hispanic, Latino

127 (60.2)

24 (42.1)

0.015

LDL-C (mg/dL), mean

123.98 (± 34.77, SD)

110.36 (± 42.47, SD)

0.013

TC (mg/dL), mean

204.13 (± 44.96, SD)

187.67 (± 50.77, SD)

0.018

HDL-C (mg/dL), mean

50.4 (± 14.1, SD)

53.9 (± 18.6, SD)

0.126

Distribution of population

IMC: Internal Medicine Clinic; CC: Cardiology Clinic; TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High density lipoprotein
cholesterol; SBP: Systolic blood pressure.

accuracy and completeness of physician documentation which may have impacted the
determination of physician adherence to guideline recommendations. Our analysis
does not account for other reasons why GDST was not implemented (e.g., patient
factors, physician attitudes towards prescribing, adverse reactions, and cost of
therapy). Additionally, our study did not account for patient adherence to prescriber
recommendations. Regardless of statin treatment, we obtained information from the
lipid panel which may not have impacted high-risk cohorts but underestimated statin
eligibility for other cohorts (e.g., patient previously prescribed statin, but at the time of
assessment patient may not have appeared to be eligible for statin therapy based on
cholesterol results).
In conclusion, our study compared the use of GDST in patients managed by general
internists and those co-managed by a cardiologist. As expected, patients with higher
cardiac risk factors and co-morbidities were more likely to be co-managed by a
cardiologist and placed on statin therapy. In terms of appropriate statin use based on
guidelines, there was no statistical difference in proportion of patients receiving GDST
between groups managed by general internists alone or co-managed with a
cardiologist; however, there was a significantly greater use of statins in patients comanaged by a cardiologist. Overall, statin use in this population is comparable to what
other studies have shown and highlights the need to design and implement strategies
to improve prescriber adherence to GDST.

ARTICLE HIGHLIGHTS
Research background
Statins have an important and well-established role in the prevention of atherosclerotic
cardiovascular disease (ASCVD). However, several studies have reported widespread
underuse of statins in various practice settings and populations.

Research motivation
Review of relevant literature reveals opportunities for improvement in the
implementation of guideline-directed statin therapy (GDST).

Research objectives
In this study, we aimed to examine the impact of cardiologist intervention on the use
of statin therapy in the ambulatory setting.
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Research methods
We conducted a retrospective chart review of patients who had at least one encounter
at the adult Internal Medicine Clinic (IMC) and/or Cardiology Clinic (CC) and who
had an available serum cholesterol test performed. The 2 comparison groups were
defined as: (1) Patients only seen by IMC; and (2) Patients seen by both IMC and CC.
Baseline characteristics of subgroups were compared.

Research result
A total of 268 patients met the inclusion criteria for this study. Approximately, 14%
had clinical ASCVD, 13% were current smokers, 66% were diabetic, and 63% were
hypertensive. Statin use was observed in 55% of the entire cohort, with moderateintensity statins being the most commonly prescribed. Overall, in the IMC-CC group,
73.6% of patients were prescribed statin therapy compared to 50.7% of patients in the
IMC group. There was no statistical difference in the use of GDST between groups.

Research conclusions
Our study compared the use of GDST in patients managed by general internists and
those co-managed by a cardiologist. Overall, statin use in this population is
comparable to what other studies have shown and highlights the need to design and
implement strategies to improve prescriber adherence to GDST.
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